The encouraging results obtained by these drugs in non RAI-responsive differentiated thyroid carcinomas in some clinical trials where the RET rearrangement was not evaluated, were more likely due to the effects on neo-angiogenesis [35]. The gene discussed is RET; the disease is thyroid gland carcinoma.